<?xml version="1.0" encoding="ISO-8859-1"?><rss version="2.0" xmlns:creativeCommons="http://backend.userland.com/creativeCommonsRssModule" xmlns:dc="http://purl.org/dc/elements/1.1/">

<channel>
<title>Neostem Company Newsfeed</title>
<link>http://www.advfn.com/amex/rss.asp?symbol=NBS</link>
<description>Neostem Company Newsfeed</description>
<language>en</language>
<pubDate>Wed, 13 Jul 2011 15:56:10 EDT</pubDate>
<lastBuildDate>Wed, 13 Jul 2011 15:56:10 EDT</lastBuildDate>
  
  
 <item>
 <title>Stem-Cell Stocks May Now Be Worth The Risk</title>
 <link>http://www.advfn.com/amex/StockNews.asp?stocknews=NBS&amp;article=48430379&amp;headline=stem-cell-stocks-may-now-be-worth-the-risk</link>
 <guid>http://www.advfn.com/amex/StockNews.asp?stocknews=NBS&amp;article=48430379&amp;headline=stem-cell-stocks-may-now-be-worth-the-risk</guid>
 <description>&#60;div class='newsbody'&#62;&#60;p&#62; --Even the most obscure story can produce double-digit stock moves, thanks in part to the companies' diminutive stock floats. &#60;/p&#62;
&#60;p&#62; --Some analysts say an investor may want to take a core long position as the stocks are so sensitive to news about clinical development and...</description>
 <pubDate>Wed, 13 Jul 2011 15:56:10 EDT</pubDate>
 </item>

</channel>
</rss>